Une étude de petite envergure a révélé que la thérapie par cellules CAR-T pourrait offrir une nouvelle méthode de gestion du VIH sur le long terme. Cette approche, déjà utilisée pour traiter certains cancers, consiste à modifier les cellules immunitaires d'un patient.
Les chercheurs adaptent ce traitement pour le VIH après avoir observé des signes précoces positifs chez deux individus. Les cellules modifiées semblent aider à contrôler le virus sans nécessiter d'intervention constante.
Rapporté par l'IA Image générée par IA
A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.
A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.
Rapporté par l'IA
Researchers have developed 3D-printed gels that mimic lymph nodes to improve the production of CAR T-cells for cancer treatment. The approach increased success rates and sped up cell growth compared with standard methods. It may help lower costs and expand access to the therapy worldwide.
A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.
Rapporté par l'IA
South Africa has started rolling out the twice-yearly HIV prevention injection lenacapavir, though success depends on managing interactions with common tuberculosis medicines.